Lipogems Enrolls 2nd Trial for Knee Osteoarthritis

Lipogems announces the first patient enrolled in the ARISE II U.S. FDA Investigational Device Exemption research study, which aims to examine investigational MicroFat versus saline injection for the treatment of Knee Osteoarthritis (OA).

Lipogems received FDA 510(k) clearance in 2018 to market a Microfragmented Adipose Tissue Transplant...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us